Conjoined triplets

A two-year diet has done more for investors than a decade of acquisitions. The drug giant still trades at a 10 pct discount to rivals – fodder for CEO Ian Read to push for a breakup. And Pfizer’s recovery should encourage others to find similar solutions to sluggish performance.